drugset
drugset / Trial / NCT04945616

To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects

NCT04945616 ↗

Phase 1 Completed 52 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupTriple-blindOther

Summary

The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender. The subjects are divided into three groups: A, B, and C, with 16 cases in each of groups A and B, and 20 cases in group C.

Timeline

Start
2021-07-13
Primary completion
2021-10-19
Completion
2022-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR2285 Small molecule — —
Background Aspirin Small molecule — —
Background Clopidogrel Small molecule — —
Background Ticagrelor Small molecule — —

Indications

thrombotic disease